Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Question
3. Background (1)
4. Background (2)
5. Purpose
6. Determining in vivo brain-to-blood efflux transport
7. Clarifying molecular mechanism of BBB transport
8. Proving transport function of candidate transporter
9. Selected substrates
10. Why GABA ?
11. GABA result: in vivo transport activity
12. GABA result: transport mechanism
13. Why D- and L-Aspartic acid?
14. Asp result: in vivo transport activity
15. Asp result: transport mechanism
16. Why homovanillic acid (HVA)?
17. HVA result: in vivo transport activity
18. HVA result: transport mechanism
19. Why indoxyl sulfate (IS), uremic toxin?
20. Indoxyl sulfate result: in vivo transport activity
21. Indoxyl sulfate result: transport mechanism
22. Why 6-mercaptopurine and 6-thioguanine?
23. 6-MP and 6-TG result: in vivo transport activity (1)
24. 6-MP and 6-TG result: in vivo transport activity (2)
25. 6-MP and 6-TG result: transport mechanism
26. Why dehydroepiandrosteron sulfate (DHEAS)?
27. DHEAS result: in vivo transport activity
28. DHEAS result: transport mechanism
29. Why 24S-hydroxycholesterol?
30. 24S-hydroxycholesterol result
31. Conclusion
32. Illustrated conclusion
33. Perspective
34. Reference (1)
35. Reference (2)
36. Reference (3)
37. Reference (4)

Topics Covered

• The blood-brain barrier is not just a static wall, but "a cerebral clearance organ"
• The BBB multiple efflux transporters play a part in CNS detoxification by pumping out endogenous compounds from the brain
• Neurotransmitters
• Neuromodulators
• Metabolites of neurotransmitters
• Uremic toxins
• Cholesterol metabolites

Links

Series:

• The Blood-Brain Barrier

Categories:

• Neuroscience
• Pharmaceutical Sciences

Therapeutic Areas:

• Neurology

Talk Citation

Terasaki, T. (2008, March 1). Brain-to-blood efflux transport of endogenous compounds and its analogue drug at the blood-brain barrier [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/OWEN4279.
Export Citation (RIS)

Publication History

• Published on March 1, 2008
• Archived on May 31, 2018

Financial Disclosures

• Prof. Tetsuya Terasaki has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.